Fortress Biotech, Inc.
FBIO
$2.76
$0.072.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.03M | 15.01M | 13.14M | 14.12M | 14.63M |
| Total Other Revenue | 606.00K | 1.40M | -- | 1.00M | -- |
| Total Revenue | 17.63M | 16.41M | 13.14M | 15.12M | 14.63M |
| Cost of Revenue | 5.96M | 13.07M | 8.73M | 12.18M | 13.92M |
| Gross Profit | 11.67M | 3.35M | 4.41M | 2.94M | 712.00K |
| SG&A Expenses | 17.42M | 38.76M | 25.66M | 23.17M | 21.99M |
| Depreciation & Amortization | 1.06M | 1.06M | 1.07M | 3.42M | 814.00K |
| Other Operating Expenses | -- | -- | -- | -4.55M | -- |
| Total Operating Expenses | 24.44M | 52.89M | 35.46M | 34.22M | 36.72M |
| Operating Income | -6.81M | -36.47M | -22.32M | -19.10M | -22.10M |
| Income Before Tax | 8.85M | -11.65M | -24.69M | -25.98M | -26.63M |
| Income Tax Expenses | 26.00K | -- | -- | 336.00K | 69.00K |
| Earnings from Continuing Operations | 8.83M | -11.65M | -24.69M | -26.32M | -26.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.98M | 27.14M | 14.11M | 19.55M | 13.83M |
| Net Income | 5.85M | 15.49M | -10.58M | -6.77M | -12.87M |
| EBIT | -6.81M | -36.47M | -22.32M | -19.10M | -22.10M |
| EBITDA | -5.65M | -35.32M | -21.13M | -17.98M | -21.14M |
| EPS Basic | 0.13 | 0.50 | -0.48 | -0.37 | -0.76 |
| Normalized Basic EPS | 0.44 | 0.11 | -0.05 | 0.18 | -0.03 |
| EPS Diluted | 0.11 | 0.45 | -0.48 | -0.37 | -0.76 |
| Normalized Diluted EPS | 0.36 | 0.10 | -0.05 | 0.18 | -0.03 |
| Average Basic Shares Outstanding | 27.24M | 26.88M | 26.45M | 26.01M | 19.70M |
| Average Diluted Shares Outstanding | 33.10M | 29.82M | 26.45M | 26.01M | 19.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 0.00% | 0.00% |